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httpcense.Abstract Background: The criteria of Light et al. have been used to make the differentiation
between transudate and exudate effusion for the past 25 years. The main problem with those criteria
is that although they identify nearly all exudates correctly, they misidentify about 20–25% of
transudates as exudates.
The plasma NT-proBNP level is a sensitive marker of cardiac dysfunction and has proved to be a
useful tool for the identiﬁcation and management of systolic and diastolic cardiac dysfunction.
Objective: The aim of this work was to study the value of pleural NT-pro brain natriuretic pep-
tide in the diagnosis of pleural effusion of different causes in comparison to the conventional diag-
nostic procedures in cases of pleural effusion.
Subjects and methods: The present study was conducted on 32 patients who suffered from pleural
effusion, they were classiﬁed according to Light’s criteria into two groups namely transudate, exu-
date, and the third group of 10 normal healthy subjects as control group.
Results: The levels of both serum and pleural ﬂuid pro-BNP in group I patients with transudate
effusion were signiﬁcantly higher than group II patients with exudate effusion (P> 0.001, 0.003)
respectively.
Conclusion: The results support the feasibility of using the pleural ﬂuid amino terminal proBNP
measurement in thoracentesis that would enhance discrimination among the different causes of
pleural effusion especially for heart failure patients. Serum and pleural ﬂuid levels of NT-pro1755448.
.com (A.H. Kassem).
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600 L.A. Banawan et al.BNP were closely correlated and measurement of NT-pro BNP in serum showed equally good diag-
nostic properties.
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Traditionally, pleural effusions have been separated into
transudative and exudative pleural effusions [1]. The primary
reason to separate transudative from exudative pleural effu-
sions is that if a patient has a transudative pleural effusion,
no investigations need to be directed toward the pleural effusion
and the systemic condition can be treated with the expectation
that the effusion will resolve. In contrast, if the patient has an
exudative pleural effusion it is important to determine the local
disease that is responsible for the effusion. Accordingly, addi-
tional laboratory tests and at time invasive tests are indicated
to demonstrate the etiology of the pleural effusion [2].
Amino-terminal brain natriuretic peptide precursor (NT-
proBNP) isamemberofa familyofvasoactivepeptidesproduced
by the heart and circulate as hormones to act in various tissues in
the body. The synthesis of this peptide is stimulated by the in-
creasedwall tension or stretching of cardiac chambers. The plas-
maNT-proBNPlevel isa sensitivemarkerofcardiacdysfunction
and has proved to be a useful tool for the identiﬁcation andman-
agement of systolic and diastolic cardiac dysfunction [3,4,5].
The criteria of Light’s [2] have been used to make the differ-
entiation between transudate and exudate effusion for the past
25 years. The main problem with those criteria is that although
they identify nearly all exudates correctly, they misidentify
about 20–25% of transudates as exudates [6,7].
The aim of this work was to study the value of pleural NT-
pro brain natriuretic peptide in the diagnosis of pleural effu-
sion of different causes in comparison to the conventional
diagnostic procedures in cases of pleural effusion.
Subjects and methods
This study enrolled 32 patients with symptomatic pleural effu-
sion admitted to the chest department, Alexandria University
Hospital and 10 normal healthy subjects as control group.
Patients were divided into two groups according to Light’s
criteria [8]:
1. Group I contains 16 patients who were diagnosed as
transudative pleural effusion.
2. Group II contains 16 patients who were diagnosed as exu-
dative pleural effusion.
Each patient signed an informed consent before inclusion in
the study. The study protocol was approved by the local ethics
committee of the Alexandria faculty of medicine.
All patients were subjected to the following: complete his-
tory taking, clinical examination, radiological evaluation
(plain chest X-ray, computed tomography of the chest, US
chest/abdomen and or pelvis), routine laboratory investiga-
tions and serum NT-proBNP level.
Thoracentesis: [9] The pleural ﬂuid analysis was carried out
including: biochemical (pH, LDH, protein and glucosecontent), bacteriological (AFS, C&S), cytological for detection
of abnormal cells, and NT-proBNP level determination.
ECG/Echocardiography, thoracoscopy, pleural biopsy and
bronchoscopy were done if needed.
Measurements of NT-BNP: serum and pleural ﬂuid NT-pro
BNP level was determined using N-terminal pro-Brain Natri-
uretic Peptide ELISAKit ProductNo.: E20 111 018033 – 96 test.
Principle of assay
The NT-proBNP enzyme linked immunosorbent assay (ELI-
SA) kit is used for the estimation of N-terminal Pro BNP level
in serum and biological ﬂuids. A puriﬁed antibody was coated
on a microwell plate and fully adsorbed on the microwell wall
to make a solid-phase carrier. Enzyme conjugation solution
afﬁnity material contains the enzyme labeled antigen. During
the experiment, by adding the sample under test and en-
zyme-linked afﬁnity material and coated on the porous incu-
bated with antibody response to be fully integrated in the
porous walls, a common competition coated on the porous so-
lid phase antibody, the formation of labeled antigen complex.
Unbonded samples were washed off upon the reaction, and a
substrate was added for reaction, the substrate developed a
blue color in the presence of enzyme, and ﬁnally developed a
yellow color in the presence of acid. A standard curve was
drawn by reading absorbance values, and concentrations of
the samples to be assayed were obtained [10].
Results
The demographic data of the three studied groups as regards
age and sex is showed in Table 1.
In group I, 11 patients (68.8%) were suffering from diabe-
tes mellitus, 7 patients (43.8%) presented with heart failure, 7
patients (43.8%) presented with liver failure and 4 patients
(25%) presented with renal impairment.
In group II, 3 patients (18.8%) were suffering from diabetes
mellitus, 8 patients presented with malignancy (50%), and six
patients (37.5%) presented with pneumonia. There was one
case (6.3%) of exterapulmonary TB and one patient (6.3%)
presented with pulmonary embolism (Table 2).
Table 3 shows that the mean pleural ﬂuid protein was
2.09 ± 0.75 g/dl ranging between 1.2 and 4.2 g/dl in group I,
while it was 4.87 ± 1.03 g/dl ranging between 3.1 and 6.8 in
group II. There was a statistically signiﬁcant increase in pleural
ﬂuid protein in group II than in group I (F= 14.098, p=
0.001*).
Applying Light’s criteria on the two studied groups we
found that:
1. There was a statistically signiﬁcant increase in pleural ﬂuid
protein in group II than in group I (p= 0.001).
2. Pleural ﬂuid/serum protein ratio, there was a statistically
signiﬁcant increase in group II than in group I (p= 0.001).
Table 1 Demographic data of the three studied groups.
Group I Group II Control P
No. % No. % No. %
Sex
Female 4 25.0 7 43.8 5 50.0 v2 = 1.981
Male 12 75.0 9 56.2 5 50.0 p= 0.371
Age
Range 33–72 21–67 26–62
Mean ± S.D 52.94 ± 10.73 51.13 ± 14.46 46.70 ± 11.11 0.457
SD= standard deviation, p is signiﬁcant at 60.05.
Table 3 Light’s criteria among the pleural effusion patients.
Parameter Group I Group II F(P)
Pleural ﬂuid protein g/dl M± SD 2.09 ± 0.75 4.87 ± 1.03 14.098(0.001*)
F/S protein ratio M± SD 0.32 ± 0.12 0.67 ± 0.12 11.079(0.001*)
F/S LDH ratio M± SD 0.43 ± 0.128 3.37 ± 2.24 12.069(0.001*)
S/F protein gradient M± SD 0.30 ± 0.65 2.40 ± 0.85 15.048(0.001*)
p: p value for F test (ANOVA).
p is signiﬁcant at 60.05 M=mean LDH= lactate dehydrogenase F/S = ﬂuid/serum.
Table 2 The prevalence of co-morbidities among the studied patient groups.
Diseases Group I (n= 16) Group II (n= 16) Test of sig.
No. % No. %
Diabetes mellitus 11 68.8 3 18.8 v2 = 8.127
p= 0.004
Heart failure 7 43.75 - - FEp= 0.007*
Malignancy - - 8 50 FEp= 0.002*
Hepatic failure 7 43.75 0 0.0 FEp= 0.007*
Renal impairment 4 25.0 0 0.0 FEp= 0.101
Pneumonia - - 6 37.5 FEp= 0.018*
Tuberculosis - - 1 6.3 FEp= 1.000
Pulmonary embolism - - 1 6.3 FEp= 1.000
p: p value for comparing the two studied groups.v2: Chi Square test.FE: Fisher Exact test.
* Statistically signiﬁcant at p 6 0.05.
Table 4 Comparison between the different studied groups according to serum pro BNP.
Group I (n= 16) Group II (n= 16) Control (n= 10) F (p)
Serum pro BNP
Min.–Max. 404.0–3393.0 246.0–874.0 186.40–223.60 14.437* (<0.001)
Mean ± SD 1587.88 ± 1091.90 615.50 ± 199.66 205.47 ± 12.09
p1 0.001
* <0.001*
p2 0.346
p: p value for F test (ANOVA) for comparing between the three studied groups.
p1 : p value for Post Hoc test (Scheffe) for comparing between group I and each other group.
p2 : p value for Post Hoc test (Scheffe) for comparing between group II and control.
* Statistically signiﬁcant at p 6.
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ratio in group II than in group I (p= 0.001).4. S/F gradient was increased in group I than in group II and
it was statistically signiﬁcant (p= 0.001).
Table 7 Median values of pro BNP among patients of group I
and group II.
N Serum pro BNP Fluid pro BNP
Group I
HF 7 2890 2897
Liver failure 6 659 654
Renal impairment 2 1122 1124
Group II
Malignancy 8 785 789.5
Pneumonia 6 447 455.5
Table 8 Correlation between serum pro BNP and pleural
ﬂuid pro BNP and Light’s criteria.
Serum pro BNP Fluid pro BNP
R P r P
Pleural ﬂuid protein 0.440* 0.012 0.445* 0.011
F/S protein ratio 0.448* 0.010 0.452* 0.009
S/F protein gradient 0.485* 0.005 0.488* 0.005
F/S LDH 0.383* 0.030 0.390* 0.027
r: Pearson coefﬁcient.
* Statistically signiﬁcant at p 6 0.05.
Table 5 Comparison between the two studied groups according to ﬂuid pro BNP.
Group I (n= 16) Group II (n= 16) t (p)
Fluid pro BNP
Min.–Max. 392.0–3412.0 282.0–849.0 3.541*(0.003)
Mean ± SD 1600.18 ± 1095.48 617.81 ± 187.07
p: p value for Student t-test.
* Statistically signiﬁcant at p 6 0.05.
Table 6 Correlation between serum pro BNP and ﬂuid pro
BNP.
Serum pro BNP
Group I Group II
Fluid pro BNP r 1.000* 0.995*
p <0.001 <0.001
r: Pearson coefﬁcient.
* Statistically signiﬁcant at p 6 0.05.
602 L.A. Banawan et al.Table 4 shows that serum pro BNP in group I ranged be-
tween 404 and 3393 pg/ml with a mean of 1587.88 ±
1091.90 pg/ml.
As regards group II the range was 246–874 pg/ml with a
mean of 615.50 ± 199.66 pg/ml. While in the control group
the range was 186.4–223.6 pg/ml with a mean of 205.47 ±
12.09 pg/ml.
There was a signiﬁcant increase in serum pro BNP in group
I than in group II and control group (p1 = 0.001
*) while there
was no signiﬁcant increase in serum pro BNP in group II than
in control group (P2 = 0.346) (Table 4).
The mean value of pro BNP in pleural effusion patients of
group I was 1600.18 ± 1095.48 pg/ml ranging between 392
and 3412 pg/ml (Table 5).
While, the mean was 617.81 ± 187.07 pg/ml ranging be-
tween 282 and 849 pg/ml among patients of group II. There
was a statistically signiﬁcant difference in pro BNP among
the two studied groups (P= 0.003*) (Table 5).
It was found that the level of proBNP was closely correlated
in serum and pleural ﬂuid in both group I and group II (Pearson
coefﬁcient r 1.000 and 0.995, respectively) (p< 0.00) (Table 6).
The median value of serum pro BNP among patients of
heart failure was 2890 and 659 pg/ml in patients of liver failure
while the median was 1122 pg/ml in patients with renal impair-
ment. Among patients of group II the median value of serum
pro BNP was 785 pg/ml in patients with malignancy while the
median was 447 pg/ml among patients with pneumonia.
The median value of pleural pro BNP among patients of
heart failure was 2897 pg/ml and 654 pg/ml in patients of
liver failure with hepatic hydrothorax, while the median
was 1124 pg/ml in patients with renal impairment. Among
patients of group II the median value of pleural pro
BNP was 789.5 pg/ml in patients with malignancy while
the median was 455.5 pg/ml among patients with pneumo-
nia (Table 7).
Table 8 shows that there was a statistically signiﬁcant neg-
ative correlation between pleural ﬂuid protein and serum and
pleural ﬂuid pro BNP (r: 0.440, 0.445 and P= 0.012,
0.011, respectively).There was a statistically signiﬁcant negative correlation be-
tween F/S protein ratio and serum and pleural ﬂuid pro BNP
(r: 0.448, 0.452 and p= 0.01, 0.009, respectively).
There was a statistically signiﬁcant negative correlation be-
tween F/S LDH ratio and serum and pleural ﬂuid pro BNP
(r: 0.383, 0.390 and p= 0.030, 0.027, respectively).
There was a statistically signiﬁcant positive correlation be-
tween S/F protein gradient and serum and pleural ﬂuid pro
BNP (r: +0.485, +0.488 and p= 0.005, 0.005, respectively).
There was a statistically signiﬁcant negative correlation be-
tween both serum and ﬂuid pro-BNP and ejection fraction in
patients of group I (r: 0.582, 0.572 and P 0.018*, 0.020*,
respectively) (Fig. 1).
Discussion
Brain natriuretic peptide (BNP) and N-proBNP are indicator
and prognostic factors for left heart failure and valuable mark-
ers for risk stratiﬁcation in acute coronary syndrome. More-
over natriuretic peptide has been demonstrated to be useful
for the differential diagnosis of acute dyspnea in emergency
department and identiﬁcation of acute heart failure in particu-
lar [5,10].
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Figure 1 Correlation between pleural ﬂuid and serum pro BNP
and ejection fraction in group I.
The value of use of amino-terminal brain naturitic peptide 603Porcel and associates [11] ﬁrst demonstrated in 2004 that
the measurement of the levels of N-terminal pro-brain natri-
uretic peptide (NT-pro-BNP) in the pleural ﬂuid was useful
in identifying patients with congestive heart failure.
Burgess and associates [12] proposed that an albumin gra-
dient (serum albumin-pleural ﬂuid albumin) of >1.2 g/dL
should be used to identify the misclassiﬁed transudates.
The present study was conducted on 32 patients. All pa-
tients suffered from pleural effusion, they were classiﬁed
according to Light’s criteria [24] into two groups namely tran-
sudate, exudate, and the third group of 10 normal healthy sub-
jects as control group.
It has been shown consistently in several studies that NT-
proBNPare related to sex, with higher values in females, and
to age, with higher values in older individuals. The sex relation
is thought to be caused by differences in metabolism [13].
In the current study we found a positive not signiﬁcant cor-
relation of NT-pro BNP in serum and pleural ﬂuid and age
which may be because the mean age was younger in our study
population (mean age was 52.94 ± 10.73 years) and 75% of
the studied patients were males.
In accordance with our study Cincin et al. [14] who studied
the amino-terminal brain natriuretic peptide (NT-proBNP)
levels in pleural ﬂuid of two groups, group I with heart failure
related pleural effusion and group II non heart failure effusion.
They found no statistical signiﬁcant differences between the
different studied groups regarding age.
In contrast Stolz et al. [15] observed signiﬁcant correlations
between BNP levels on hospital admission and age in patients
with acute exacerbation of COPD (r= 0.425, p= 0.001).
In the present study the levels of both serum and pleural
ﬂuid pro-BNP were signiﬁcantly higher in group I patients
with transudate effusion than in group II patients with exudate
effusion (p> 0.001, 0.003), respectively.
In accordance with our study Cincin et al. [14] found that,
patients with HF related pleural effusion had signiﬁcantly
higher pleural NTproBNP levels than other patients
(p< 0.001). Pleural and serum NT-proBNP measures were
closely correlated. An NT-proBNP cut-off value of
P2300 pg/mL in pleural ﬂuid had a sensitivity of 70.8%,and speciﬁcity of 97.6% for discriminating transudates caused
by HF from exudates.
In agreement with our study Kolditz et al. [16] evaluated
the diagnostic accuracy of N-terminal-pro-B-type natriuretic
peptide (NT-proBNP) levels, measured simultaneously in ser-
um and pleural ﬂuid, in identifying pleural effusions due to
heart failure. They found that levels of NT-proBNP in serum
and pleural ﬂuid were signiﬁcantly elevated, 10-fold, in pa-
tients with acute decompensated left heart failure compared
to patients with noncardiac effusions. Moreover, elevated
NT-proBNP levels displayed a high sensitivity and speciﬁcity
in detecting cardiac transudates in the patient group over a rel-
atively large range of cut-off values.
In accordance with our study Porcel et al. [11] retrospec-
tively examined 117 patients with pleural effusion, of whom
44 (38%) were diagnosed as having pleural effusion due to
heart failure. The pleural ﬂuid levels of NT-proBNP were sig-
niﬁcantly higher in patients with cardiac transudates than in
patients with effusion due to other causes. The pleural ﬂuid
NT-proBNP or BNP cut-off values for discriminating pleural
effusion with heart failure are variable from 1176 to 4000 pg/
mL [4,21].
In agreement with our study Tomcsanyi et al. [17] com-
pared NT-proBNP levels in serum and pleural ﬂuid in 14 pa-
tients with pleural effusion due to congestive heart failure
and 14 patients with pleural exudates of various causes. They
found signiﬁcantly higher levels of NT-proBNP in both serum
and pleural ﬂuid from patients with cardiac effusions (median
6,295 versus 277 ng/L in pleural ﬂuid; 5713 versus 236 ng/L in
serum) and suggested a diagnostic cut-off point for detecting
cardiac transudates of 599–1457 ng/L.
Gegenhuber et al. [18] evaluated the diagnostic accuracy of
NT-proBNP measured in serum and pleural ﬂuid for the iden-
tiﬁcation of pleural effusions caused by heart failure in 93 pa-
tients referred for thoracentesis.
Both were signiﬁcantly higher in patients with effusions
caused by heart failure than in patients with pleural effusions
attributable to other causes.
Among the studied population we found that median levels
of pleural ﬂuid NT-proBNP were higher in heart failure pa-
tients (2897 pg/ml) than in renal impairment patients
(1124 pg/ml), malignant effusions (789.5 pg/ml), liver failure
patients (668 pg/ml) and parapnuemonic effusion (445.5 pg/
ml).
Another study [13] evaluated the clinical utility of pleural
ﬂuid NT-proBNP in patients with pleural effusion. They found
that median levels of pleural ﬂuid NT-proBNP among patients
with heart failure were signiﬁcantly higher (3310 pg/mL) than
in those patients with hepatic hydrothorax (531 pg/mL), malig-
nant pleural effusions (733 pg/mL), tuberculous pleural effu-
sions (214 pg/mL), and parapneumonic pleural effusions
(294 pg/mL).
In our study we found that the levels of NT-pro BNP was
closely correlated in serum and pleural ﬂuid in both group I
and group II (Pearson coefﬁcient r 1.000, 0.995, respectively)
and (p< 0.001).
Han et al. (2008) [13] found that, levels of NT-proBNP
measurement in pleural and in serum were closely correlated
(Spearman’s coefﬁcient of rank correlation 0.928; p< 0.001)
for pleural effusion patients.
604 L.A. Banawan et al.The study by Kolditz et al. [16] demonstrated a strong cor-
relation of NT-proBNP concentrations in serum and pleural
ﬂuid and equal diagnostic accuracies for serum and pleural
ﬂuid NT-proBNP measurements for the discrimination of
pleural effusions attributable to heart failure.
This close correlation between pleural ﬂuid and serum
NTproBNP may be explained by that serum NTproBNP is de-
rived from cardiac ventricular myocytes. Due to its small size
(8.5 kDa), the peptide can easily diffuse from the blood into
the pleural space. Because there is no evidence that NT-proB-
NP is synthesized by mesothelial cells, they assume that pleural
NT-proBNP levels are proportional to serum NT-proBNP lev-
els [13].
Therefore, Gegenhuber et al. [18] claimed that it may not be
necessary to perform diagnostic thoracentesis in patients with
serum NT-proBNP concentrations exceeding a cut-off value,
making the diagnosis of heart failure as the underlying cause
of pleural effusion is very likely in these patients. However,
in all other patients with serum NTproBNP concentrations be-
low such a cut-off value, early diagnostic thoracentesis may be
necessary to determine whether the effusion is exudative or
transudative in nature.
Porcel et al. [19] suggested two potential cutoff values for
NT-proBNP, 1300 and 1500 pg/mL. A cutoff value of 1300
provided a sensitivity of 95.6% (95% CI, 0.89–0.988) and a
speciﬁcity of 87.9% (95% CI, 0.794–0.938), whereas a cutoff
value of 1500 pg/mL demonstrated a sensitivity of 93.3%
(95% CI, 0.861–0.975) and a speciﬁcity of 89% (95% CI,
0.807–0.946). Previously recommended cutoff values vary from
1176 to 4000 pg/mL for pleural ﬂuid NT-proBNP [13].
Ann et al. [20] found a NT-proBNP value of 2000 pg/mL to
have a sensitivity of 80% (95% CI, 0.58–0.92) and a speciﬁcity
of 73% (95% CI, 0.61–0.83), whereas a cutoff value of
5,000 pg/mL had a sensitivity of 45% (95% CI, 0.26–0.66)
and a speciﬁcity of 97% (95% CI, 0.89–0.99). The discrepancy
between these studies regarding both the degree of correlation
as well as sensitivity and speciﬁcity may relate to a speciﬁc
immunoassay.
In agreement with Light’s criteria in our study population
we found that, there was a statistically signiﬁcant increase of
pleural ﬂuid protein in group II than in group I (P< 0.001),
F/S protein ratio showed a statistically signiﬁcant increase in
group II than in group I (P< 0.001), ﬁnally S/F protein gra-
dient showed a statistically signiﬁcant increase in group I than
in group II (p< 0.001), ﬂuid/serum LDH ratio showed a sta-
tistically signiﬁcant increase in group II than in group I
(P< 0.001).
In the study population of Cincin et al. [14], they found
eight HF patients were misclassiﬁed as exudates by Light’s cri-
teria, 5 of which received diuretics before thoracentesis. All
misclassiﬁed patients had pleural NTproBNP levels higher
than 1165 pg/mL, which predicted HF associated transudates
with 95.8% sensitivity and 85.7% speciﬁcity [18].
Romeo-Candeira et al. [21] asserted that if pleural ﬂuid
meets exudative Light’s criteria but the effusion is thought to
be due to heart failure, the serum to pleural ﬂuids protein gra-
dient should be examined. And if this gradient is greater than
3.1 g/dL, the pleural ﬂuid in all probability is due to heart fail-
ure and additional diagnostic studies are not indicated. But
other studies showed that pleural ﬂuid NT-proBNP is more
accurate than protein gradient [13,17].In our study we found a statistically signiﬁcant negative
correlation between both serum and pleural ﬂuid proBNP
and ejection fraction in patients of group I with transudate
effusion (r: 0.582, 0.572, respectively and P 0.018*,
0.020*, respectively).
In accordance Inoue et al. [22] found a signiﬁcant correla-
tion between plasma BNP level and % ejection fraction
(r= 0.41, p= 0.0197).
Simon et al. [23] showed a signiﬁcant negative correlation
between N terminal BNP levels and LVEF and a signiﬁcant
positive correlation between N terminal BNP and LV end-dia-
stolic dimension.
Viscente et al. [24] found a good correlation of NT-pro
BNP plasma levels with LV two-dimensional cavity areas
(LVEDA, LVESA).
Bay et al. [25] found that the concentrations of NT-pro
BNP increase with decreasing left ventricular ejection fraction
(LVEF).
Groenning et al. [26] found a statistically signiﬁcant nega-
tive correlation between N terminal BNP and LV ejection frac-
tion (r= 0.75; P< 0.0001). They concluded that NT-
proBNP is a powerful marker for LV dimensions and systolic
function in patients with heart failure.
Conclusion
Measurement of Pleural ﬂuid NT-pro BNP levels is probably
the best way to identify patients with pleural effusion due to
heart failure that meet exudative criteria by lights.
The results support the feasibility of using the pleural ﬂuid
amino terminal proBNP measurement in thoracentesis that
would enhance discrimination among the different causes of
pleural effusion especially for heart failure patients.
Serum and pleural ﬂuid levels of NT-pro BNP were closely
correlated and measurement of NT-pro BNP in serum showed
equally good diagnostic properties. Serum and pleural ﬂuid
levels of NT-proBNP showed a signiﬁcant negative correlation
with ejection fraction and the parameters of Light’s criteria.
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